This is a routine, immaterial insider sale cluster. The dollar amount is too small to warrant any trading action. Monitor for any upcoming material filings (earnings, pipeline updates) that could provide context, but these sales alone carry no signal.
RARE drugs
RARE drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Aug 4 $25.81entry
- T+1 · 3mo ago −3.41%α −3.21% · $24.93
- T+5 · 3mo ago +4.46%α +4.56% · $26.96
- T+20 · 3mo ago 0.00%α +1.24% · $25.81
- T+60 · 20d ago −35.10%α −35.48% · $16.75
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two C-suite insiders at Ultragenyx (CFO and EVP/Chief Legal Officer) sold a combined $164K in open-market sales on August 3, 2026, at $24.92 per share. The total value is only ~0.007% of the $2.5B market cap, making this a trivial cluster by proportionality standards. The sales are not clustered with any recent material corporate event in the provided context, and the dollar amount is well below the threshold for signaling concern, this is routine portfolio diversification or tax planning, not informed selling.
Key Financial Metrics
Key Facts
- CFO Howard Horn sold 4,696 shares for $117K on 2026-08-03
- EVP/CLO Karah Parschauer sold 1,900 shares for $47K on 2026-08-03
- Total cluster value of $164K represents ~0.007% of $2.5B market cap
- Both sales were open-market transactions at $24.92 per share
- No recent earnings, guidance, or material corporate event in the provided context to connect to these sales
Financial Impact
Trivial, $164K total sales, ~0.007% of market cap
Risk Factors
- No material risk identified from this filing
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RARE-1785871541587 |
Track record
22 reports on RARE
8 of 10 bullish or bearish reports moved the stock their way by T+5. Best: +48.73% at T+60 after the Apr 2, 2026 report. 9 of 10 went positive at some point.
Filters
- Nov 13, 20263d ago SC 13G/A Neutral 2/10 Entry $16.08 Now $15.90 −1.12% settles Nov 20
- Nov 10, 20266d ago SC 13G Neutral 3/10 Entry $16.14 Now $15.90 −1.49% settles Nov 17
- Nov 3, 202613d ago 8-K Mixed 6/10 No price data
- Nov 3, 202613d ago Press Release Bearish 6/10 Entry $17.16 to $16.70 Now $15.90 +7.34% ▲ +2.68% +1.77% vs SPY
- Oct 30, 202617d ago SC 13G/A Neutral 2/10 Entry $16.10 to $15.43 Now $15.90 −1.24% ▼ −4.16% −1.46% vs SPY
- Oct 20, 202627d ago SC 13G Neutral 3/10 Entry $15.92 to $16.75 Now $15.90 −0.13% ▲ +5.21% +5.66% vs SPY
- Oct 19, 202628d ago 8-K Neutral 4/10 Entry $15.07 to $16.08 Now $15.90 +5.51% ▲ +6.70% +6.85% vs SPY
- Oct 14, 20264w ago 8-K Bullish 6/10 Entry $14.90 to $15.92 Now $15.90 +6.71% ▲ +6.85% +6.39% vs SPY
- Oct 7, 20265w ago 8-K Bullish 6/10 Entry $14.89 to $14.90 Now $15.90 +6.78% ▲ +0.07% +1.05% vs SPY
- Sep 17, 20268w ago Press Release Bullish 8/10 Entry $14.50 to $14.77 Now $15.90 +9.66% ▲ +1.86% +1.01% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers